Cormorant Asset Management, LP

Cormorant Asset Management, LP reported 60 holdings worth US$1.49B as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Cormorant Asset Management, LP reported 60 holdings worth US$1.49B as of Sep 30, 2026. Largest: Parabilis Medicines, Inc., Praxis Precision Medicines, Inc. and Rapport Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
60
Value as reported
US$1.49B

The filing in full

CompanySharesValue as reported% of portfolio
Parabilis Medicines, Inc.4.62MUS$149M10.0%
Praxis Precision Medicines, Inc.500KUS$146M9.8%
Rapport Therapeutics, Inc.2.46MUS$82.6M5.5%
Edgewise Therapeutics, Inc.1.86MUS$75.5M5.1%
BridgeBio Oncology Therapeutics, Inc.17.9MUS$73.3M4.9%
Erasca, Inc.5MUS$73.3M4.9%
BlossomHill Therapeutics, Inc.3.61MUS$67.4M4.5%
Adlai Nortye Group Ltd.3.98MUS$63.7M4.3%
Dianthus Therapeutics, Inc.500KUS$44M3.0%
Abivax SA425KUS$42.1M2.8%
Bright Minds Biosciences Inc.800KUS$39.9M2.7%
Electra Therapeutics, Inc.3.37MUS$37.9M2.5%
Oruka Therapeutics, Inc.400KUS$33.3M2.2%
Attovia Therapeutics, Inc.1.79MUS$30.7M2.1%
Sensei Biotherapeutics, Inc.1.03MUS$30.6M2.1%
Latigo Biotherapeutics, Inc.1.82MUS$30.3M2.0%
AgomAb Therapeutics NV2.47MUS$27.4M1.8%
Opus Genetics, Inc.5.5MUS$26.6M1.8%
Climb Bio, Inc.2.11MUS$24.2M1.6%
Freenome, Inc.1.43MUS$22.5M1.5%
MBX Biosciences, Inc.375KUS$22M1.5%
Biohaven Ltd.1.51MUS$20.2M1.4%
ADARx Pharmaceuticals, Inc.963KUS$19.2M1.3%
EyePoint, Inc.5.75MUS$18.8M1.3%
Tango Therapeutics, Inc.700KUS$17.5M1.2%
BridgeBio Pharma, Inc.250KUS$16.4M1.1%
Cue Biopharma, Inc.625KUS$16.2M1.1%
Corbus Pharmaceuticals Holdings, Inc.2.34MUS$16M1.1%
BioAge Labs, Inc.2.24MUS$15.9M1.1%
Alumis Inc.2.08MUS$15.3M1.0%
Olema Pharmaceuticals, Inc.1.75MUS$15.1M1.0%
Helix Acquisition Corp. III1.3MUS$13.8M0.93%
Spyre Therapeutics, Inc.125KUS$11.1M0.75%
Definium Therapeutics, Inc.275KUS$10.5M0.70%
Aclaris Therapeutics, Inc.1.75MUS$9.21M0.62%
Amylyx Pharmaceuticals, Inc.300KUS$8.73M0.59%
Cabaletta Bio, Inc.4.5MUS$8.64M0.58%
Inhibrx Biosciences, Inc.50,000US$5M0.34%
Kailera Therapeutics, Inc.400KUS$4.57M0.31%
Jade Biosciences, Inc.300KUS$4.21M0.28%
iBio, Inc.3.57MUS$4.21M0.28%
Tarsus Pharmaceuticals, Inc.50,000US$3.93M0.26%
Roivant Sciences Ltd.100KUS$3.66M0.25%
Enliven Therapeutics, Inc.75,000US$3.44M0.23%
Odyssey Therapeutics, Inc.125KUS$2.78M0.19%
Boundless Bio, Inc.940KUS$2.36M0.16%
Insmed Incorporated20,000US$2.28M0.15%
Braveheart Bio, Inc.70,000US$1.41M0.09%
Research Alliance Corporation III125KUS$1.35M0.09%
Arcutis Biotherapeutics, Inc.50,000US$1.32M0.09%
Arrowhead Pharmaceuticals, Inc.15,000US$982K0.07%
Cogent Biosciences, Inc.30,000US$961K0.06%
Structure Therapeutics, Inc.30,000US$938K0.06%
Vaxcyte, Inc.15,000US$854K0.06%
Altimmune, Inc.0US$00.00%
Crinetics Pharmaceuticals, Inc.0US$00.00%
Damora Therapeutics, Inc.0US$00.00%

Source

Download original · View original at SEC

Related